Juvenile Idiopathic Arthritis Jia clinical trials

Explore recruiting juvenile idiopathic arthritis jia clinical trials.

Recruiting juvenile idiopathic arthritis jia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Juvenile Idiopathic Arthritis Jia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

I1F-MC-RHCG: Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Germany, Spain, France, Belgium, Czechia, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A3921145 - A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)

Spain, Belgium, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis

Spain, Bulgaria, France, Belgium, Germany, Greece +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

I4V-MC-JAHW: An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Italy, Germany, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

I4V-MC-JAHX: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA)

Belgium, Poland, France, Germany, Spain, Denmark +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open Label Extension (OLE), multiple dose study to evaluate pharmacokinetics, safety, tolerability and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with juvenile idiopathic arthritis (JIA).

France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Juvenile Idiopathic Arthritis Jia trials by city

Juvenile Idiopathic Arthritis Jia in Toronto Juvenile Idiopathic Arthritis Jia in Vancouver Juvenile Idiopathic Arthritis Jia in Montreal Juvenile Idiopathic Arthritis Jia in Calgary Juvenile Idiopathic Arthritis Jia in Edmonton Juvenile Idiopathic Arthritis Jia in Ottawa Juvenile Idiopathic Arthritis Jia in Winnipeg Juvenile Idiopathic Arthritis Jia in Quebec City Juvenile Idiopathic Arthritis Jia in Hamilton Juvenile Idiopathic Arthritis Jia in Kitchener Juvenile Idiopathic Arthritis Jia in London Juvenile Idiopathic Arthritis Jia in Halifax Juvenile Idiopathic Arthritis Jia in New York Juvenile Idiopathic Arthritis Jia in Los Angeles Juvenile Idiopathic Arthritis Jia in Chicago Juvenile Idiopathic Arthritis Jia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease